NLS Pharmaceutics Presents Latest Clinical and Preclinical Data at SLEEP 2023

Author's Avatar
May 04, 2023
  • Oral presentation sharing significant phase 2 results of Mazindol ER in Adults with Narcolepsy Type 1 and Type 2
  • Five abstracts demonstrating NLS focus on and investment in hypersomnia disorders and rare and complex neurologic diseases